Curasight

"During the second quarter of 2024, we have continued to build on our successes from the past year. We have enrolled the first patient in our phase 2 trial with uTRACE in prostate cancer and showed the rapid progress in our partnership with Curium, receiving the second milestone payment under this collaboration", stated Curasight's CEO Ulrich Krasilnikoff. "Additionally, we announced a capital raise aimed at further strengthening the company's finances. The financing includes a directed share issue, a loan facility, and warrants which has initially provided DKK 27.8 million with the potential total fund raise of up to DKK 120 million, extending our cash runway well into the second half of 2025."

Q2 (2024-04-01 - 2024-06-30)

• Gross loss amounted to kDKK -9,001 (kDKK -9,029)
• Operating loss amounted to kDKK -10,969 (kDKK -10,658)
• Loss before tax amounted to kDKK -12,112 (kDKK -10,658)
• Loss for the period amounted to kDKK -10,737 (kDKK -8,312)
• Total assets amounted to kDKK 28,847 (kDKK 46,331)
• Equity ratio amounted to 43.9% (95.8%)
• Earnings per share amounted to DKK -0.54 (DKK -0.41)

H1 (2024-01-01 - 2024-06-30)

• Gross loss amounted to kDKK -16,385 (kDKK -13,685)
• Operating loss amounted to kDKK -20,345 (kDKK -16,842)
• Loss before tax amounted to kDKK -21,479 (kDKK -16,844)
• Loss for the period amounted to kDKK -18,729 (kDKK -13,138)
• Total assets amounted to kDKK 28,847 (kDKK 46,331)
• Equity ratio amounted to 43.9% (95.8%)
• Earnings per share amounted to DKK -0.94 (DKK -0.66)

Numbers in parenthesis are the numbers from the same period in 2023.